Dr. Janine Collinge
Dr. Collinge has over 11 years of experience in practice as a pediatric ophthalmologist. She has helped foster excellent vision care for children at the Dean McGee Eye Institute and the University of Oklahoma Health Science Center, Connecticut Children’s and the Helen DeVos Children’s Hospital. Dr. Collinge has expertise in managing a wide range of childhood eye problems, from common disorders like amblyopia and strabismus to rare vision issues like pediatric cataracts and pediatric uveitis. She has won awards for teaching, service to her profession and service to her community. At Children’s Eye Care of Connecticut, Dr. Collinge hopes to continue to support the needs of her community through compassionate, exceptional eye care for children.
EDUCATION AND TRAINING
Undergraduate
University of Delaware
Medical School
Rutgers/UMDNJ Robert Wood Johnson Medical School
Internship
Christiana Care Health System
Residency
Washington Hospital Center & Georgetown University Hospital, Chief Resident
Fellowship
Indiana University School of Medicine and Riley Hospital for Children
Professional Experience
Dean McGee Eye Institute and OU Children’s Hospital
Clinical Associate Professor
Connecticut Children’s and UConn Health
Assistant Professor
Helen DeVos Children’s Hospital
Pediatric Ophthalmologist
RESEARCH
Janine E. Collinge, MD, FAAP. Vernal keratoconjunctivitis can lead to vision loss if untreated. AAP News: Focus on Ophthalmology. May 1, 2024
​
Collinge J. Classifying Retinopathy of prematurity. Review of Ophthalmology 2022; July 10. https://www.reviewofophthalmology.com/article/classifying-retinopathy-of- prematurity
​
With the PEDIG group: Freedman, Sharon F., et al. ;Low-and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes." Ophthalmology 129.10 (2022): 1120-1128.
Pineles SL, Henderson RJ, Repka MX, Heidary G, Liu GT, Waldman AT, Borchert MS, Khanna S, Graves JS, Collinge JE, Conley JA, Davis PL, Kraker RT, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group. The Pediatric Optic Neuritis Prospective Outcomes Study: Two-Year Results. Ophthalmology. 2022 Mar 29:S0161-6420(22)00234-2.
With the PEDIG group: Kraker, Raymond T., et al. "Choice of dose level for a randomized clinical trial of low-dose bevacizumab vs laser for type 1 retinopathy of prematurity." JAMA ophthalmology 139.10 (2021): 1143-1144.
Crouch ER, Kraker RT, Wallace DK, Holmes JM, Repka MX, Collinge JE, Bremer DL, Gray ME, Smith HA, Steinkuller PG; Writing Committee for the Pediatric Eye Disease Investigator Group. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.JAMA Ophthalmol. 2020 Jan 1;138 (1):14-20.
Abhishek Bavle, Michael Anderson, Michael Confer, Hilarie Simpson,Theresa Gavula,Naina Gross,Maria Lim,René McNall-Knapp,Janine Collinge. Ocular complications after proton radiation for childhood brain tumors. Authorea. September 10, 2020
Kovarik JJ, Doshi PN, Collinge JE, Plager DA. Outcome of pediatric patients referred for papilledema. J AAPOS. 2015 Aug;19(4):344-8.
Collinge JE, Sprunger DT. Update in pediatric optic neuritis.Curr Opin Ophthalmol. 2013 Sep;24(5):448-52
Collinge JE, Simirskii VN, Duncan MK. Expression of tissue plasminogen activator during eye development. Exp Eye Res. 2005 Jul; 81(1): 90-6
